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Abstract
Background: Copy number variants (CNVs) have been shown to increase risk for physical anomalies, developmental,
psychiatric and medical disorders. Some of them have been associated with changes in weight, height, and other
physical traits. As most studies have been performed on children and young people, these effects of CNVs in middle-
aged and older people are not well established. The UK Biobank recruited half a million adults who provided a variety
of physical measurements. We called all CNVs from the Affymetrix microarrays and selected a set of 54 CNVs implicated
as pathogenic (including their reciprocal deletions/duplications) and that were found in five or more persons. Linear
regression analysis was used to establish their association with 16 physical traits relevant to human health.
Results: 396,725 participants of white British or Irish descent (excluding first-degree relatives) passed our quality control
filters. Out of the 864 CNV/trait associations, 214 were significant at a false discovery rate of 0.1, most of them novel.
Many of these traits increase risk for adverse health outcomes: e.g. increases in weight, waist-to-hip ratio, pulse rate and
body fat composition. Deletions at 16p11.2, 16p12.1, NRXN1 and duplications at 16p13.11 and 22q11.2 produced the
highest numbers of significant associations. Five CNVs produced average changes of over one standard deviation for
the 16 traits, compared to controls: deletions at 16p11.2 and 22q11.2, and duplications at 3q29, the Williams-Beuren
and Potocki-Lupski regions. CNVs at 1q21.1, 2q13, 16p11.2 and 16p11.2 distal, 16p12.1, 17p12 and 17q12 demonstrated
one or more mirror image effects of deletions versus duplications.
Conclusions: Carriers of many CNVs should be monitored for physical traits that increase morbidity and mortality.
Genes within these CNVs can give insights into biological processes and therapeutic interventions.
Keywords: UK Biobank, CNV, BMI, Waist, Pulse, Weight, Height, Obesity, Anthropometric
Introduction
Human height, weight and other anthropometric traits
are highly heritable. Genetic factors contribute up to
80% of height [1, 2]. Genome-wide association studies
(GWAS) suggest that the total additive effect of single
nucleotide variants (SNVs) explain 56% of variance in
height and 27% of body mass index (BMI) variability [3].
The heritability of hand grip strength has been estimated
at 56% [4]. Resting heart rate, systolic and diastolic blood
pressure are also highly heritable, with estimates of 61,
54 and 49% respectively [5].
While SNVs tend to have small effect sizes, large copy
number variants (CNVs) have been shown to have
profound effects on weight and height, with 16p11.2 de-
letions and duplications providing striking examples [6].
Other recognised CNVs with large effect sizes on phys-
ical traits are deletions at distal 16p11.2, associated with
obesity [7], and at 1q21.1, associated with microcephaly
and short stature [8]. Failure to thrive has been de-
scribed in some carriers of 3q29 duplications [9] while
short stature has been associated with the 22q11.2 and
22q11.2 distal deletions [10]. Individuals with severe
early-onset obesity have an increased rate of large and
rare deletions [11]. Obesity can be a feature in rare syn-
dromic monogenic disorders [12], which include several
of the CNVs analysed in the current study: 1q21.1 dele-
tion, 15q11-q13 duplication, 16p11.2 and 16p11.2 distal
deletions and 22q11.2 duplication.
Most of the published research has been based on
children or young people referred for genetic testing for
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developmental delay, congenital malformations and aut-
ism spectrum disorders, i.e. some of the most affected
individuals. Such individuals may not be typical of car-
riers of CNVs, and importantly for long term health out-
comes, the impact of these CNVs in middle-aged and
older adults (> 40 years), especially in those who have
not been diagnosed as CNV carriers in early life, is not
well described. In addition, most reports focus on a sin-
gle, or at most a limited number of CNVs, making it dif-
ficult to perform comparative studies of the impact of
individual CNVs on physical measures. Another poten-
tial problem is that small sample sizes will miss subtle
differences in physical traits.
The largest study on CNVs and anthropometric
measures was performed on 191,161 unrelated Euro-
pean adults [13]. It assessed systematically the effect
of CNVs on BMI, weight, height, and waist/hip ratio
in 25 component studies of the Genetic Investigation
of Anthropometric Traits (GIANT) Consortium,
combined with the first release of UK Biobank data,
approximately a third of the total sample. A
genome-wide analysis implicated seven CNV regions:
1q21.1 (distal part: 145–145.9 Mb), 3q29 (two sub-re-
gions), 7q11.23 (72.61 72.75 Mb), chr11: 26.97–27.19
Mb; 16p11.2 distal, 16p11.2; chr18: 55.81–56.05 Mb
(Mb intervals in hg18). These loci were associated at
genome-wide significance with at least one of the four
traits in a mirror effect model in which deletions and
duplications affect the trait in opposite directions. No
common CNVs were significantly associated with the
traits, despite the higher statistical power to detect
such associations.
Here we report an analysis of the full UK Biobank co-
hort. We tested 54 CNVs that have been proposed to be
pathogenic and were carried by at least five participants.
We analysed these CNVs for association with a set of 16
physical traits (Table 1 and Methods), that include the
anthropometric traits analysed by the GIANT Consor-
tium (weight, height, BMI, waist/hip ratio), as well as
other physical traits: pulse rate, blood pressure, arm
strength, peak expiratory volume, heel bone mineral
density, and the fat percentage of legs, arms and trunk.
These traits are associated with adverse health outcomes
and increased mortality [14–19].
Results
We tested 16 physical traits (Table 1) for association with
54 CNVs (Methods). This analysis produced 864 pheno-
type/CNV associations (Additional file 1: Table S1). Of
those 75 survive conservative Bonferroni correction for
864 tests (p < 5.8 × 10− 5). Using the Benjamini-Hochberg’s
method, 214 associations were significant at a 10%
false discovery rate (FDR) level (marked in bold in
Additional file 1: Table S1). Images of the changes in
the physical traits associated with each CNV, and
their 95% confidence intervals (95%CI), are shown in
Additional file 2: Figure S1 and on our institutional
website (http://kirov.psycm.cf.ac.uk).
Table 2 summarises the significant findings. The table
is restricted to CNVs that have at least one significant
association at FDR = 0.1, with the direction of the effect
indicated with + or -. To simplify the presentation, we
grouped together the three fat percentage measures to
indicate any change on arm, leg or trunk fat % measures
Table 1 List of physical measures from the UK Biobank data included in the analysis. (Details in Methods)
Measure Biobank Field ID Procedure Unit Number of people tested
Birthweight 20022 Self-report kg 225,138
weight 21002 Scales kg 395,584
Height 50 Standing height cm 395,854
BMI 21001 Weight/height2 kg/m2 395,441
Hand grip strength right 47 Grip strength device kg 395,129
Waist circumference 48 Tape measure cm 396,037
Hip circumference 49 Tape measure cm 395,992
Waist to hip ratio 48/49 Waist/hip ratio 395,954
Leg fat percentage right 23111 Bioimpedance % 389,777
Arm fat percentage right 23119 Bioimpedance % 389,722
Trunk fat percentage 23127 Bioimpedance % 389,569
Pulse rate 102 Automated reading bpm 373,789
BP systolic 4080 Automated reading mmHg 370,501
BP diastolic 4079 Automated reading mmHg 370,511
Peak expiratory flow 3064 Spirometry litres/min 361,464
Heel bone mineral density 3148 Ultrasound bone densitometry g/cm2 228,405
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Table 2 CNVs with significant associations at FDR = 0.1 for physical traits. “+” or “-” indicate the direction of the change. Fat %
indicates a significant change on any one of arm, leg or trunk fat % measurements. The last column shows the average absolute
difference (normalised coefficients from linear regression) of the 16 tests for each CNV
CNV Weight Height BMI Hand grip
strength
Fat % Pulse rate BP Peak expiratory
flow
Heel bone mineral
density
Waist/hip
ratio
Average
difference (B)
TAR del + 0.37
TAR dup – 0.24
1q21.1 del – – – – – 0.65
1q21.1 dup + + + + + 0.24
NRXN1 del + + – + – – + 0.25
2q11.2 del + + + + + 0.75
2q13 del + + – + – 0.52
2q13 dup – – – – 0.38
2q13dup NPHP1 – 0.04
2q21.1 dup – 0.20
3q29 del – – + + 0.99
3q29 dup + + + 1.77
WBS dup – – + + 1.12
7q11.23dup distal + – 0.55
13q12.12 dup – – – 0.17
13q12del CRYL1 + 0.12
15q11.2 del – + + + – + + 0.16
15q11.2 dup + – + 0.05
PWS dup – – + 0.71
15q11q13 del BP3 BP4 + – 0.83
15q11q13 dup BP3 BP4 + 0.29
15q13.3 del + – + 0.50
15q13.3 dup – – + + + 0.29
15q13.3 del CHRNA7 – 0.67
15q24 dup + + 0.76
16p11.2 del + – + – + + – + 1.56
16p11.2 dup + – – – – – 0.23
16p11.2 distal del + + + + 0.71
16p11.2 distal dup – – – – – – – 0.36
16p12.1 del + – + – + + – + 0.38
16p12.1 dup – 0.11
16p13.11 del – – 0.20
16p13.11 dup + + + + – + + 0.16
17p12del HNPP – + + 0.40
17p12dup CMT1A – – + – – – 0.93
Potocki Lupski – – + 1.00
17q12 del – + 0.71
17q12 dup – 0.25
22q11.2 del – – + + – – + 1.35
22q11.2 dup + – + – + + 0.21
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and we don’t show the waist and hip circumferences, as
the waist/hip ratio reflects this information. Figure 1
(a-c) shows the distribution of changes for the three
CNVs with the largest number of significant associations
(13 each): 16p11.2 deletion, 16p12.1 deletion and
16p13.11 duplication. The significance also depends on
sample size, so these are not necessarily the most patho-
genic CNVs. A better measure for overall pathogenicity
could be the average absolute effect size, which does not
depend on the sample size (Table 2, last column). Five
CNVs produced an average effect size change of over
one SD for the 16 phenotypes: deletions at 16p11.2 and
22q11.2, and duplications at 3q29, the Williams-Beuren
and Potocki-Lupski regions.
Mirror phenotypes
A number of reciprocal deletions/duplications at the
same locus show significant differences in opposite di-
rections. We decided to use a simple definition for a
CNV that produces a mirror phenotype: at least one
measure should be changed in opposite directions, both
significantly different from controls at FDR = 0.1. Using
this definition, we find seven mirror image CNVs: 1q21.1,
2q13, 16p11.2, 16p11.2 distal, 16q12.1, 17p12 and 17q12
(Fig. 2 a-g). Inspection of the directions of the effects of all
CNVs (Additional file 2: Figure S1) suggests that more
CNVs might produce genuine mirror phenotypes, if tested
in larger samples. Our results confirm three of those re-
ported by Macé et al. [13],: 16p11.2, 16p11.2 distal and
1q21.1, while 3q29 also suggests multiple mirror pheno-
types in our data (Additional file 2: Figure S1), but none of
them reached significance, most likely due to the small
number of observations (9 deletions and 5 duplications).
The other four findings by Macé et al. could not be tested
in our data: in the 7q11.23 region we found only one dele-
tion and the 11p14.2 and 18q21.32 regions were not on
our list. Here we report associations on 12 more physical
traits and identified four more significant loci. Further
comparisons with physical, social and mental health mea-
sures were reported by Macé et al. [13] for two CNVs:
16p11.2 and 16p11.2 distal, affirming the high pathogen-
icity of these two loci. Our significant findings for 2q13,
16p12, 17p12 and 17q12 were not reported in the previous
study, presumably because some specific measures were
not tested in that study (e.g. blood pressure pulse
rate, fat %), or due to statistical power issues. We
note that although the two studies complement each
other, they are not fully independent, as the first third
of the UK Biobank sample was also used by Macé et
al. [13]. They also differed in the methods used: we
tested a pre-defined list of 54 loci, while Macé et al.
deployed a genome-wide scan.
Discussion
Novel associations
About one quarter of all possible CNV/phenotype asso-
ciations were significant at FDR = 0.1, suggesting mul-
tiple effects on physical traits by many pathogenic
CNVs. Some of these associations are already known
from previous large case series, e.g. 16p11.2 deletion/du-
plication and 16p11.2 distal deletion (Introduction),
from studies on individuals with syndromic short stature
or obesity, and from a large study on 26 cohorts [13],
supporting the validity of this dataset and our methods.
We show that the majority of these CNVs (41 of the 54)
impact on at least one physical trait. Many significant as-
sociations have not been reported before in systematic-
ally assessed cohorts, and certainly not as part of the
same analysis, where identical methods are used, to
allow comparisons between CNVs. As examples, we find
that deletions in NRXN1, a CNV so far known to
increase risk for schizophrenia and autism spectrum
disorders [20–22], are associated with a plethora of ad-
verse changes, producing 11 significant results, such as
Fig. 1 Effect sizes for the physical measurements for the three CNVs with the highest number of significant associations. Effects sizes means are
the normalised z-score values (standard deviation changes) from linear regression analysis after correction with co-variates, produced with the
glm function of R. The figures show the mean changes in z-scores and the 95% confidence intervals of the changes. a) 16p11.2 deletion,
b) 16p12.1 deletion, c) 16p13.11 duplication
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increased weight, BMI, waist/hip ratio, fat percentage in
arms, legs and trunk, and a faster pulse rate. NRXN1
carriers also show reductions in muscular strength,
peak expiratory flow and heel bone mineral density.
Carrier status of 15q11.2 deletions and duplications
have not been consistently associated with medical or
anthropometric changes, although deletions increase
risk for neurodevelopmental disorders [21, 23]. We
now show that deletion carriers have significant
changes in over half of the traits, most notably reduc-
tions in height and birth weight, and increases in bone
mineral density and waist/hip ratio. 15q11.2 duplication
carriers have increased BMI, fat percentage and waist
circumference and reduced muscular strength. The
magnitudes of the changes associated with 15q11.2 are
small (e.g. deletion carriers are only 1.5 cm shorter in
height on average), but the very large sample size of the
UK Biobank (~ 1600 deletion and ~ 1900 duplication
carriers) allows small changes to be detected with high
statistical confidence. Another notable finding is the as-
sociation of 22q11.2 duplications with 10 measures. Al-
though high rates of psychiatric disorders have been
recorded for this CNV [24], due to the extreme pheno-
typic variability of this condition, its true pathogenicity
has been regarded as unclear [25]. We report on a
much larger sample (266 carriers) and observe that
central obesity (increased BMI and waist-to-hip ratio) is
the leading feature in duplication carriers, making this
CNV potentially highly pathogenic in relation to
health-related outcomes [18, 26].
CNVs cause adverse effects of likely medical relevance
We note that most (although not all) of the observed ef-
fects are likely to be adverse for health. Thus, all 35 sig-
nificant associations with hand grip strength and peak
expiratory flow are in the direction of reduced perform-
ance. Reduced hand grip strength and peak expiratory
flow are associated with increased mortality [14, 16].
Most associations with pulse rate and blood pressure are
in the direction of higher values, indicating a worse car-
diovascular performance. Many CNVs cause increased
weight/ fat percentage/ central obesity (increased waist/
hip ratio), all well-known factors that increase morbidity
and mortality [15, 18, 26]. We have indeed shown that
in this population, carriers of this set of CNVs have in-
creased mortality and morbidity for many common
medical disorders [27]. There are notable exceptions:
lower weight (and/or other obesity-related measures) are
found in carriers of deletions at 1q21.1 and duplications
at 2q13, 13q12.12, 16p11.2 and distal 16p11.2. The po-
tential protective effects of lower weight or fat percent-
age appear to be offset by other adverse consequences of
these CNVs. Thirteen CNVs lead to shorter height, while
only three are associated with increased height: 1q21.1
duplications, and deletions at 13q12 (CRYL1) and
16p11.2. BMI on its own is not sufficient to assess
weight, height and obesity changes. For example, carriers
of 1q21.1 deletions are on average 6.0 cm shorter and
4.8 kg lighter, while carriers of the reciprocal 1q21.1 du-
plications are 2.2 cm taller and 3.3 kg heavier. Despite
these substantial changes, both types of carriers have an
Fig. 2 Effect sizes for the physical measurements for the seven CNVs with significant “mirror phenotypes”, marked with arrows: a) 1q21.1: height
and weight, b) 2q13: weight, BMI, waist and hip circumference, c) 16p11.2: height, weight, BMI, waist and hip circumference, leg and trunk fat
percentage, and heel bone mineral density d) 16p11.2 distal: weight, BMI, waist and hip circumference and trunk fat percentage, e) 16p12.1: arm,
leg and trunk fat percentage, diastolic blood pressure, f) 17p12: diastolic blood pressure, g) 17q12: pulse rate
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average BMI. A widely accepted measure of obesity, as-
sociated with adverse effect on health outcomes, is the
waist/hip ratio, which has been shown to better predict
the risk for myocardial infarction [26]. We find this sig-
nificantly increased in carriers of 13 CNVs, while no
CNV caused a significantly reduced ratio, i.e. we do not
see any protective effects for medical outcomes, even for
CNVs that lead to reduced weight. Our findings that du-
plications at 15q11.2, 15q13.3, 16p13.3, 22q11.2 and de-
letions at NRXN1 are among the CNVs with the highest
rates of adverse changes on physical traits, were unex-
pected and raise important issues regarding the manage-
ment of such carriers.
Are the effects primary or secondary?
Some of the changes in physical traits could be due to
life-style differences among CNV carriers, or to medica-
tion given for diseases caused by the CNVs, rather than
to a direct biological effect from gene dosage changes.
Current knowledge of CNV effects are largely restricted
to childhood, while the UK Biobank population is com-
posed of middle-aged and older adults (ranging between
40 and 69 years old at recruitment), a difference that
may result in lifestyle-related effects in this cohort. Re-
duced muscular strength, lower peak expiratory flow,
faster pulse rate, increased weight and fat percentage
can all be consequences of reduced exercise and
life-style changes. Having a pathogenic CNV might make
the person less likely to exercise, due to medical, cogni-
tive or social problems. However, it appears that lifestyle
is unlikely to account for all the changes we report.
Thus, it cannot explain why at least seven CNV loci
have opposite (mirror) phenotypes in deletion and dupli-
cation carriers (Fig. 2) and why four CNVs lead to re-
duced weight (1q21.1 deletion, 2q13 duplication,
13q12.12 duplication and 16p11.2 distal duplication).
The 1q21.1 duplication carriers present with increased
height and weight, which together with the macroceph-
aly reported in children with this duplication [8] sug-
gests that this is an overgrowth syndrome [28], although
with a variable expressivity [8]. Such observations indi-
cate that many of the differences are a direct conse-
quence of gene dosage changes, rather than just
secondary to life-style or social factors. In fact, each
CNV has its own unique signature of physical traits,
which becomes apparent on a heatmap image (Fig. 3).
Having a diagnosis of a neurodevelopmental disorder
(with the resulting medication intake and life-style
changes) can not account for the observed changes ei-
ther. Only 1179 persons in the tested sample (0.3%) had
a diagnosis of “mental retardation”, autism or schizo-
phrenia. This low rate is due to the recognised “healthy
volunteer” selection bias that operated during the UK
Biobank recruitment, resulting in this population being
less socioeconomically deprived, and having lower mor-
bidity and mortality than the general population [29].
We re-analysed the data after excluding these 1179
people and present the comparison of the results in
Additional file 3: Table S3. Out of the 214 results origin-
ally significant at FDR = 0.1, only 8 lost their significance,
while a similar number of new ones reached significance.
The effect sizes remained essentially identical, apart
from some fluctuations on three of the rarest CNVs
where a high proportion of carriers were diagnosed with
neurodevelopmental disorders: two out of nine carriers
of 3q29 deletions had schizophrenia, and two cases of
“mental retardation” were found in both Potocki-Lupski
Syndrome duplications (out of five carriers) and 22q11.2
deletions (out of 10 carriers). This is best captured on a
scatterplot included in Additional file 3: Table S3, where
the outliers belong largely to these three CNVs.
Conclusions
Our work provides an unbiased comparison of physical
measures between adult CNV carriers, as all Biobank par-
ticipants were assessed with the same methods and blindly
to their CNV status. Our findings of adverse changes in
basic physical characteristics indicate that carriers of these
CNV could benefit from general monitoring for cardiovas-
cular risk factors. It is tempting to envisage the targeting
of genes or biochemical pathways in order to improve
weight or fat distribution in humans. From this perspec-
tive, the CNVs with the most pronounced “mirror” pheno-
types (Fig. 2) are likely to contain the most promising
candidate genes, as gene dosage changes lead to reciprocal
changes in the measurements.
Materials and methods
CNV calling
We downloaded from the UK Biobank the raw intensity
(CEL) files from Affymetrix BiLEVE (N~ 50,000) and
Axiom (N~ 450,000) arrays and processed them with Affy-
metrix Power Tools (www.affymetrix.com/estore/partner-
s_programs/programs/developer/tools/powertools.affx) and
PennCNV [30]. We followed the same CNV calling pipeline
that we described previously [31].
Criteria for choosing CNVs for analysis
We called a list of 92 CNVs proposed to be pathogenic in
two widely accepted sources [23, 32]. These lists included
CNV regions that lead to genomic disorders or clinically
significant phenotypes, reported in databases or multiple
publications (Additional file 4: Table S2). Most of them
have been shown to statistically increase risk for develop-
mental delay [23]. The table lists the 92 CNVs and the rea-
sons for exclusion or retention in the analysis. The
reciprocal deletions/duplications of known genomic disor-
ders were also included in the source publications and in
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the current study, even if the evidence for their pathogen-
icity in unclear, in order to study potential mirror pheno-
types and so-far unconfirmed pathogenicity. We excluded
CNVs with fewer than five observations, and three small
CNV loci that produced calls predominantly on arrays
with poor QC, i.e. likely to generate false-positive calls.
This left 54 CNVs suitable for analysis.
Physical traits
We obtained data from the UK Biobank on tests which
were performed at the assessment centres and described
as “physical measurements” (biobank.ctsu.ox.ac.uk/crys-
tal/docs/Bodycomposition.pdf ). These include anthropo-
metric measures (height, weight, BMI, hip and waist
circumference), body fat content, hand grip strength,
spirometry, ultrasound heel bone densitometry and
self-reported birthweight (Table 1). Body fat content is
estimated from the bioimpedance measures performed
with a Tanita BC418MA body composition analyser. We
also included pulse rate and blood pressure, as recorded
at the assessment centres. In order to maximise statis-
tical power and simplify the presentation of the results,
we only used tests collected on > 50% of individuals and
excluded variables correlated at > 0.9, such as measures
collected on left and right arm or leg. We therefore only
analysed measures performed on the right arm or right
leg and averaged the two pulse rate measures that were
performed at the same initial visit. Following research
that highlights the importance of the waist to hip ratio
[26], we added this measure too, resulting in a set of 16
variables.
Statistical analysis
We filtered out poorly performing arrays using the follow-
ing cut-off criteria: genotyping call rate < 0.96, > 30 CNVs
per person, a waviness factor of < − 0.03 & > 0.03 & LRR
standard deviation of > 0.35. We excluded people who
self-report to be other than white British or Irish, and
first-degree relatives (using the kinship coefficients data).
This left 396,725 people for analysis. The tested variables
followed normal distributions, therefore we did not fur-
ther transform the data prior to analysis, other than to
normalise all measures into z-scores, for a uniform pres-
entation. We used linear regression analysis (glm) in R
(version 3.3.2) to test the effect of the CNV carrier status
on each measure (in z-score differences). We used the
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same set of co-variates for all associations: sex, age, array
type (Axiom/BiLEVE), Townsend deprivation index (as a
measure of the socioeconomic status) and the first 15
principal components from the genetic analysis, as pro-
vided by the UK Biobank. We also provide the changes in
non-normalised (original) units, to give a more real-world
view of the effect of CNV carrier status (e.g. kg, beats
per minute, mmHg). We did not control for education
or occupation, as we have shown that these are likely to
be consequences of CNV carrier status [31]. A Bonfer-
roni correction for 864 test gives a level of significance
of p < 5.8 × 10− 5, which is conservative, given many of
the measures are correlated (e.g. BMI and waist/hip
ratio). As many true associations were expected, it is
more appropriate to use the Benjamini-Hochberg
false-discovery rate (FDR) method [33]. We accepted
FDR = 0.1 as our significance threshold, reasoning that
10% of false positives is a reasonable trade-off for this
type of analysis (Additional file 1: Table S1).
Additional files
Additional file 1: Table S1. All results from linear regression analysis.
Separate tables are provided for each CNV. (DOCX 1040 kb) (XLSX 335 kb)
Additional file 2: Figure S1. Images of the changes in the physical
traits (normalised z-score values) associated with each CNV and their 95%
confidence intervals (95%CI). (XLSX 335 kb) (DOCX 1040 kb)
Additional file 3: Table S3. Comparison of all associations before and
after the exclusion of 1179 people with a neurodevelopmental diagnosis:
schizophrenia, autism and “mental retardation”. “new” refers to results
obtained after the exclusion of these people. The scatter plot compares
the normalised z-score values form linear regression analysis before and
after the exclusions. The few outliers are generated from three CNVs: 3q29
deletions, Potocki-Lupski Syndrome duplications and 22q11.2 deletions
where a disproportionate number of carriers had neurodevelopmental
disorders (details in Discussion). (XLSX 14 kb) (XLSX 197 kb)
Additional file 4: Table S2. List of the 92 CNVs considered for analysis.
“Significant (Coe, 2014)” indicates the CNVs that have been shown to be
significantly associated with developmental delay, autism spectrum
disorders or multiple congenital anomalies in that study [23]. “Genomic
disorder (Dittwald et al, 2013)” indicates the CNVs included in the study
by Dittwald et al. [32] as implicated in genomic disorders or clinically
significant phenotypes. “Unreliable” indicates those CNVs (mostly telomeric)
that produced calls predominantly on arrays that failed QC. This indicates
that they could generate false-positive calls even on arrays that pass QC and
therefore were excluded from analysis. “Rare” CNVs are those with < 5
observations, also excluded from analysis. (XLSX 197 kb) (XLSX 14 kb)
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